Madrigal Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Madrigal Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MDGL

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. 

CEO
William J. Sibold
CEOWilliam J. Sibold
Employees
915
Employees915
Headquarters
West Conshohocken, Pennsylvania
HeadquartersWest Conshohocken, Pennsylvania
Founded
2000
Founded2000
Employees
915
Employees915

MDGL Key Statistics

Market cap
10.39B
Market cap10.39B
Price-Earnings ratio
-34.91
Price-Earnings ratio-34.91
Dividend yield
—
Dividend yield—
Average volume
326.33K
Average volume326.33K
High today
$462.07
High today$462.07
Low today
$446.61
Low today$446.61
Open price
$459.57
Open price$459.57
Volume
364.40K
Volume364.40K
52 Week high
$615.00
52 Week high$615.00
52 Week low
$393.61
52 Week low$393.61

Stock Snapshot

Madrigal Pharmaceuticals(MDGL) stock is priced at $447.35, giving the company a market capitalization of 10.39B. It carries a P/E multiple of -34.91.

On 2026-10-18, Madrigal Pharmaceuticals(MDGL) stock moved within a range of $446.61 to $462.07. With shares now at $447.35, the stock is trading +0.2% above its intraday low and -3.2% below the session's peak.

Trading volume for Madrigal Pharmaceuticals(MDGL) stock has reached 364.4K, versus its average volume of 326.33K.

Over the past 52 weeks, Madrigal Pharmaceuticals(MDGL) stock has traded between a high of $615.00 and a low of $393.61.

Over the past 52 weeks, Madrigal Pharmaceuticals(MDGL) stock has traded between a high of $615.00 and a low of $393.61.

MDGL News

Simply Wall St 17h
Did Genetic Response Data Just Shift Madrigal Pharmaceuticals Investment Narrative? - Simply Wall Street

...

Did Genetic Response Data Just Shift Madrigal Pharmaceuticals Investment Narrative? - Simply Wall Street
TipRanks 2d
Madrigal’s Rezdiffra Moves Into Real‑World Combo Use: What Investors Should Watch

Madrigal (MDGL) announced an update on their ongoing clinical study. The phase 4 study “Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidit...

TipRanks 2d
Madrigal Expands Resmetirom Into Cardio-Metabolic Territory With New HFpEF Trial

Madrigal (MDGL) announced an update on their ongoing clinical study. The study “Resmetirom in Patients With MASH and HFpEF” tests Madrigal’s liver drug in peop...

Analyst ratings

95%

of 21 ratings
Buy
95.2%
Hold
4.8%
Sell
0%

People also own

Based on the portfolios of people who own MDGL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.